Sensory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: Neglected Immunotherapy- Responsive Sensory Neuropathy
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background and Purpose To report an improvement with immunotherapy in 34 (85%)/40 patients who required an immunotherapy among 56 patients with sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired, chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy that had progressed for >2 months; and 2) definite electrophysiological and/or biopsy evidence of demyelinating neuropathy. Results Fifty-six patients with sensory CIDP were identified. Evidence of demyelination was obtained from by the routine motor nerve conduction study (NCS) in 39 (70%) patients, from a nerve biopsy in 10, and from a near-nerve needle sensory NCS in 7 patients. The most prominent laboratory abnormality was a high protein level in the cerebrospinal fluid in 21 (49%) of 43 tested patients. Immunotherapy was required in 41 (79%) of the 52 followed-up patients. An improvement with immunotherapy was observed in 36 (88%)/41 patients. In three patients, motor weakness developed in 5–8 years’ follow-up period and so, their diagnosis was changed to CIDP. Conclusions Sensory CIDP is responded to an immunotherapy in 88% of the treated patients. Sensory CIDP was diagnosed by the routine motor NCS in 70% of patients and by a sural nerve biopsy in 18% of patients. Thus, sensory CIDP should be recognized as a treatable CIDP variant among the different types of “idiopathic sensory neuropathy.”
Abstract
Background and Purpose To report an improvement with immunotherapy in 34 (85%)/40 patients who required an immunotherapy among 56 patients with sensory chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Methods Sensory CIDP was diagnosed when two inclusion criteria are met: 1) acquired, chronic progressive or relapsing symmetrical or asymmetrical sensory polyneuropathy that had progressed for >2 months; and 2) definite electrophysiological and/or biopsy evidence of demyelinating neuropathy. Results Fifty-six patients with sensory CIDP were identified. Evidence of demyelination was obtained from by the routine motor nerve conduction study (NCS) in 39 (70%) patients, from a nerve biopsy in 10, and from a near-nerve needle sensory NCS in 7 patients. The most prominent laboratory abnormality was a high protein level in the cerebrospinal fluid in 21 (49%) of 43 tested patients. Immunotherapy was required in 41 (79%) of the 52 followed-up patients. An improvement with immunotherapy was observed in 36 (88%)/41 patients. In three patients, motor weakness developed in 5–8 years’ follow-up period and so, their diagnosis was changed to CIDP. Conclusions Sensory CIDP is responded to an immunotherapy in 88% of the treated patients. Sensory CIDP was diagnosed by the routine motor NCS in 70% of patients and by a sural nerve biopsy in 18% of patients. Thus, sensory CIDP should be recognized as a treatable CIDP variant among the different types of “idiopathic sensory neuropathy.”
참고문헌 (30)
- Oh SJ, ""Chronic sensory demyelinating neuropathy" : chronic inflammatory demyelinating polyneuropathy presenting as a pure sensory neuropathy", J Neurol Neurosurg Psychiatry, 55, pp.677~680 (1992)
- Chin RL, "Sensory CIDP presenting as cryptogenic sensory polyneuropathy", J Peripher Nerv Syst, 9, pp.132~137 (2004)
- Sinnreich M, "Chronic immune sensory polyradiculopathy : a possibly treatable sensory ataxia", Neurology, 63, pp.1662~1669 (2004)
- Shelly S, "Expanding the spectrum of chronic immune sensory polyradiculopathy : CISP-plus", Neurology, 96, pp.e2078~e2089 (2021)
- Ayrignac X, "Sensory chronic inflammatory demyelinating polyneuropathy : an under-recognized entity?", Muscle Nerve, 48, pp.727~732 (2013)
- Doneddu PE, "Atypical CIDP : diagnostic criteria, progression and treatment response. Data from the Italian CIDP database", J Neurol Neurosurg Psychiatry, 90, pp.125~132 (2019)
- van Dijk GW, "Development of weakness in patients with chronic inflammatory demyelinating polyneuropathy and only sensory symptoms at presentation : a longterm follow-up study", J Neurol, 246, pp.1134~1139 (1999)
- Berger AR, "Late motor involvement in cases presenting as"chronic sensory demyelinating polyneuropathy"", Muscle Nerve, 18, pp.440~444 (1995)
- Shouman K, "Focal sensory chronic inflammatory demyelinating polyneuropathy(CIDP)", Muscle Nerve, 63, pp.E46~E49 (2021)
- Oh SJ, "Chronic inflammatory axonal polyneuropathy", J Neurol Neurosurg Psychiatry, 91, pp.1175~1180 (2020)
- Dalakas MC, "Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies", Ther Adv Neurol Disord, 11, pp.1756285617746640~ (2018)
- Oh SJ, "Clinical Electromyography: Nerve Conduction Studies" (2003), Lippincott Williams & Wilkins
- Odabasi Z, "Diagnostic value of the near-nerve needle sensory nerve conduction in sensory inflammatory demyelinating polyneuropathy", Muscle Nerve, 57, pp.414~418 (2018)
- Oh SJ, "Color Atlas of Nerve Biopsy Pathology" (2002), CRC Press
- Fehmi J, "Nodes, paranodes and neuropathies", J Neurol Neurosurg Psychiatry, 89, pp.61~71 (2018)
- Oh SJ, "Subacute demyelinating polyneuropathy responding to corticosteroid treatment", Arch Neurol, 35, pp.509~516 (1978)
- Oh SJ, "Subacute inflammatory demyelinating polyneuropathy", Neurology, 61, pp.1507~1512 (2003)
- Oh SJ, "Multifocal sensory demyelinating neuropathy : report of a case", Muscle Nerve, 56, pp.825~828 (2017)
- Menon D, "Treatment approaches for atypical CIDP", Front Neurol, 12, pp.653734~ (2021)
- Nobile-Orazio E, "Chronic inflammatory demyelinating polyradiculoneuropathy and variants : where we are and where we should go", J Peripher Nerv Syst, 19, pp.2~13 (2014)
- Joint Task Force of the EFNS and the PNS, "European Federation of Neurological Societies", Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision, 2010, pp.15, 1~9
- Van den Bergh PYK, "European Academy of Neurology", Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy : report of a joint task force-second revision, 2021, pp.28, 3556~3583
- Łukawska M, "Pediatric CIDP : diagnosis and management. A single-center experience", Front Neurol, 12, pp.667378~ (2021)
- Michaelides A, "Pain in chronic inflammatory demyelinating polyradiculoneuropathy : a systematic review and meta-analysis", Pain Ther, 8, pp.177~185 (2019)
- Ohkoshi N, "Ataxic form of chronic inflammatory demyelinating polyradiculoneuropathy : clinical features and pathological study of the sural nerves", Eur Neurol, 45, pp.241~248 (2001)
- Ayrignac X, "Focal CIDP presenting as chronic progressive monomelic sensory neuropathy", Muscle Nerve, 47, pp.143~144 (2013)
- Vallat JM, "Diagnostic value of nerve biopsy for atypical chronic inflammatory demyelinating polyneuropathy : evaluation of eight cases", Muscle Nerve, 27, pp.478~485 (2003)
- Botez SA, "Sensory neuropathies, from symptoms to treatment", Curr Opin Neurol, 23, pp.502~508 (2010)
- Martinez AR, "Sensory neuronopathy and autoimmune diseases", Autoimmune Dis, 2012, pp.873587~ (2012)
- Gwathmey KG, "Sensory neuronopathies", Muscle Nerve, 53, pp.8~19 (2016)